ABEO Stock Overview
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Abeona Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.65 |
| 52 Week High | US$9.36 |
| 52 Week Low | US$2.34 |
| Beta | 1.25 |
| 1 Month Change | -13.96% |
| 3 Month Change | -42.27% |
| 1 Year Change | -54.72% |
| 3 Year Change | -95.12% |
| 5 Year Change | -99.30% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Here's Why Abeona Therapeutics (NASDAQ:ABEO) Must Use Its Cash Wisely
Mar 02
Here's Why Abeona Therapeutics (NASDAQ:ABEO) Can Manage Its Debt Despite Losing Money
Aug 17Despite Lacking Profits Abeona Therapeutics (NASDAQ:ABEO) Seems To Be On Top Of Its Debt
Apr 28Independent Director Paul Mann Just Sold A Bunch Of Shares In Abeona Therapeutics Inc. (NASDAQ:ABEO)
Feb 21How Much Did Abeona Therapeutics'(NASDAQ:ABEO) Shareholders Earn From Share Price Movements Over The Last Three Years?
Jan 19What Kind Of Investors Own Most Of Abeona Therapeutics Inc. (NASDAQ:ABEO)?
Dec 15
Shareholder Returns
| ABEO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.5% | 0.8% | 2.8% |
| 1Y | -54.7% | 7.1% | -9.2% |
Return vs Industry: ABEO underperformed the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: ABEO underperformed the US Market which returned -9.2% over the past year.
Price Volatility
| ABEO volatility | |
|---|---|
| ABEO Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ABEO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: ABEO's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1974 | 90 | Vish Seshadri | https://www.abeonatherapeutics.com |
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders.
Abeona Therapeutics Inc. Fundamentals Summary
| ABEO fundamental statistics | |
|---|---|
| Market Cap | US$45.52m |
| Earnings (TTM) | -US$89.03m |
| Revenue (TTM) | US$4.35m |
10.5x
P/S Ratio-0.5x
P/E RatioIs ABEO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABEO income statement (TTM) | |
|---|---|
| Revenue | US$4.35m |
| Cost of Revenue | US$1.44m |
| Gross Profit | US$2.90m |
| Other Expenses | US$91.94m |
| Earnings | -US$89.03m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.18 |
| Gross Margin | 66.80% |
| Net Profit Margin | -2,048.67% |
| Debt/Equity Ratio | 0% |
How did ABEO perform over the long term?
See historical performance and comparison